×
Avadel Pharmaceuticals Price/Book Ratio 2010-2024 | AVDL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Avadel Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
View More
Avadel Pharmaceuticals Price/Book Ratio 2010-2024 | AVDL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Avadel Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$82.4B
Takeda Pharmaceutical (TAK)
$44.4B
Merck (MKKGY)
$21.6B
Astellas Pharma (ALPMY)
$21.1B
Sandoz Group AG (SDZNY)
$19.8B
United Therapeutics (UTHR)
$16.7B
Summit Therapeutics (SMMT)
$14B
Shionogi (SGIOY)
$12.7B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$10.7B
Madrigal Pharmaceuticals (MDGL)
$7B
Orion OYJ (ORINY)
$6.8B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$5.7B
Corcept Therapeutics (CORT)
$5B
Crinetics Pharmaceuticals (CRNX)
$4.5B
PTC Therapeutics (PTCT)
$3.1B
Dyne Therapeutics (DYN)
$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.4B
Soleno Therapeutics (SLNO)
$2.2B
Recursion Pharmaceuticals (RXRX)
$1.8B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Ocular Therapeutix (OCUL)
$1.6B
Harrow (HROW)
$1.6B
NewAmsterdam Pharma (NAMS)
$1.6B
Xencor (XNCR)
$1.5B
ARS Pharmaceuticals (SPRY)
$1.5B